Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD)
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of eculizumab for the treatment of dry AMD as evaluated
by the change in drusen volume and area of geographic atrophy.